BioNTech Announces Pricing of Initial Public Offering
October 10 2019 - 3:16AM
Business Wire
BioNTech SE (“BioNTech”), a clinical-stage biotechnology company
focused on patient-specific immunotherapies for the treatment of
cancer and other serious diseases, today announced the pricing of
its initial public offering of 10,000,000 American Depositary
Shares (“ADSs”) representing 10,000,000 ordinary shares at a public
offering price of $15.00 per ADS, for gross proceeds of
$150,000,000. In addition, BioNTech has granted the underwriters a
30-day option to purchase up to an additional 1,500,000 ADSs at the
public offering price. The ADSs are expected to begin trading on
the Nasdaq Global Select Market on October 10, 2019 under the
ticker symbol “BNTX.”
All ADSs to be sold in the offering are being offered by
BioNTech. The offering is expected to close on October 15, 2019,
subject to the satisfaction of customary closing conditions.
J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB
Leerink are acting as lead joint book-running managers for the
offering. Canaccord Genuity, Bryan, Garnier & Co. and Berenberg
are acting as joint book-running managers for the offering and
Wolfe Capital Markets and Advisory, Kempen and Mirae Asset
Securities are acting as co-managers for the offering.
A registration statement relating to the ADSs being sold in this
offering has been filed with the Securities and Exchange Commission
and was declared effective on October 9, 2019. The offering is
being made only by means of a prospectus. Copies of the final
prospectus relating to the offering may be obtained, when
available, for free by visiting EDGAR on the SEC’s website at
www.sec.gov. Alternatively, copies of the final prospectus, when
available, may be obtained from J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, or by telephone at (866) 803-9204, or by
e-mail at prospectus-eq_fi@jpmchase.com; BofA Securities, Inc.,
NC1-004-03-43; 200 North College Street, 3rd Floor, Charlotte,
North Carolina 28255-0001, Attention: Prospectus Department, or by
e-mail at dg.prospectus_requests@baml.com; UBS Securities LLC,
Attention: Prospectus Department, 1285 Avenue of the Americas, New
York, New York 10019, or by telephone at (888) 827-7275, or by
e-mail at olprospectusrequest@ubs.com; or SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, Massachusetts 02110, or by telephone at (800) 808-7525,
ext. 6132, or by e-mail at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities law of any
such state or jurisdiction.
About BioNTech
BioNTech was founded in 2008 on the understanding that every
cancer patient’s tumor is unique and therefore each patient’s
treatment should be individualized. Its cutting-edge pipeline
includes individualized mRNA-based product candidates, innovative
chimeric antigen receptor T cells, novel checkpoint
immunomodulators, targeted cancer antibodies and small molecules.
BioNTech has established relationships with seven pharmaceutical
collaborators, including Eli Lilly and Company, Genmab, Sanofi,
Bayer Animal Health, Genentech, a member of the Roche Group,
Genevant and Pfizer, and has published over 150 peer-reviewed
publications on its scientific approach.
Forward-Looking Statements
This press release contains forward-looking statements,
including with respect to the expected closing of BioNTech’s
initial public offering. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions,
including that the conditions to the closing of the initial public
offering are not satisfied. BioNTech undertakes no obligation to
update any such forward-looking statements after the date hereof to
conform to actual results or changes in expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191010005276/en/
BioNTech SE Michael Boehler, MD, Head of Global External
Communications Tel: +49 (0)6131 9084 1640 Email:
Michael.Boehler@biontech.de For all media inquiries: Trophic
Communications Gretchen Schweitzer / Stephanie May, PhD Tel: +49
(0)89 23 88 77 30 or +49 171 185 56 82 Email: May@trophic.eu
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Sep 2023 to Sep 2024